Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma: This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue

L. Castagna, S. Bramanti, R. Devillier, B. Sarina, R. Crocchiolo, S. Furst, J. El-Cheikh, A. Granata, C. Faucher, S. Harbi, L. Morabito, J. Mariotti, S. Puvinathan, P. J. Weiller, C. Chabannon, D. Mokart, C. Carlo-Stella, R. Bouabdallah, A. Santoro, D. Blaise

Research output: Contribution to journalArticle

Abstract

We investigated the use of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of advanced Hodgkin lymphoma (HL). Sixty-two consecutive HL patients underwent haplo-HSCT. Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. At 100 days, the cumulative incidence of grades 2-3 and grades 3-4 acute GVHD was 23% and 4%, respectively. The chronic GVHD (cGVHD) cumulative incidence was 16%, with one patient experiencing severe cGVHD. The 3-year OS, PFS, relapse rates and 1-year non-relapse mortality (NRM) were 63%, 59%, 21% and 20%, respectively. Uncontrolled disease status and high hematopoietic cell transplantation comorbidity index (HCT-CI) were associated with lower OS, whereas PBSC was an independent protective factor. Uncontrolled disease and HCT-CI >2 was predictive for NRM. Finally, disease status other than CR was predictive of relapse. In conclusion, haplo-HSCT is a valid treatment in advanced HL, offering excellent rates of survival and acceptable toxicities.

Original languageEnglish
Pages (from-to)683-688
Number of pages6
JournalBone Marrow Transplantation
Volume52
Issue number5
DOIs
Publication statusPublished - May 1 2017

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this